PMDA drug package insert
パブロンエースＰｒｏ−X微粒
PMDA OTC drug · 大正製薬(株) · package insert May 1, 2026
Key facts
| Brand names | パブロンエースＰｒｏ−X微粒 |
|---|---|
| Companies | 製造販売元／大正製薬(株) |
| Product type | OTC drug |
| OTC risk class | 第「２」類医薬品 |
| OTC dosage form | 散剤 |
| OTC effect category | かぜ薬（内用） |
| Package insert date | May 1, 2026 |
| PMDA document key | 400059_K2307000003 |
| PMDA company code | 400059 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: